

31st January, 2018

BSE Limited

1st Floor, New Trading Wing,
Rotunda Bldg, P.J. Towers,
Dalal Street, Fort,
Mumbai- 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra-Kurla Complex,
Mumbai – 400 051

Dear Sir / Madam,

Ref: BSE Scrip Code: 532979
NSE Symbol: PIRPHYTO

Sub: Outcome of Board Meeting held today:
Financial Results for the quarter and nine months ended 31st January, 2018

Kindly refer to our letter dated 24th January, 2018 on the subject.

At the Board Meeting held today, the Board approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31st January, 2018. The Financial Highlights as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed. The said results have been subjected to Limited Review by the Auditors of the Company and a copy of their Limited Review Report is enclosed.

The meeting commenced at 11.00 a.m. and concluded at 11.45 a.m.

Request you to please take the above on record and oblige.

Thanking you,

Yours truly,
For **Piramal Phytocare Limited**


Maneesh Sharma
Company Secretary

Encl. a/a

Piramal Phytocare Limited

CIN : L73100MH2001PLC132523

Registered Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, India
Secretarial Dept : Piramal Tower Annexe, 1st Floor, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013.
T +91 22 3046 7953 F +91 22 3046 7855

piramalphytocare.com

Price Waterhouse Chartered Accountants LLP

The Board of Directors
Piramal Phytocare Limited
Piramal Tower,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai – 400 013

1. We have reviewed the unaudited financial results of Piramal Phytocare Limited (the “Company”) for the quarter ended December 31, 2017 which are included in the accompanying ‘Statement of Standalone unaudited results for the quarter and nine months ended December 31, 2017’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The review of the unaudited financial results of the Company for the quarters ended September 30, 2016 and December 31, 2016, and audit of the financial statements of the Company for the year ended March 31, 2017 were carried out by another firm of chartered accountants who issued their unmodified conclusion, vide their reports dated October 25, 2016 and February 8, 2017, and unmodified opinion vide their report dated April 12, 2017 respectively.
Our conclusion is not qualified in respect of the matters stated in paragraph 5 above.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016
Chartered Accountants



Jeetendra Mirchandani
Partner
Membership Number 048125

Mumbai
January 31, 2018

Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West)
Mumbai - 400 028
T: +91 (22) 66691500, F: +91 (22) 66547804 / 07

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)


PIRAMAL PHYTOCARE LIMITED

Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

(Rs. in Lakhs)

Particulars	3 months ended 31/12/2017	Preceding 3 months ended 30/09/2017	Corresponding 3 months ended in the previous year 31/12/2016	Year to Date Figures for Current Period Ended 31/12/2017	Year to Date Figures for Previous Period Ended 31/12/2016	Previous Year ended 31/03/2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations	587	1,216	141	2,165	322	413
Other Income	13	4	5	21	19	29
Total Income	600	1,220	146	2,186	341	442
Expenses						
Cost of raw and packing materials consumed	47	13	21	89	93	143
Purchase of Stock-in-Trade	138	749	7	1,109	17	18
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8)	(4)	16	(3)	4	5
Employee benefits expense	293	305	12	856	68	101
Finance Cost	-	-	-	-	-	0
Depreciation and amortisation expense	1	1	1	3	3	4
Business Promotion and Franchise Expenses	477	337	-	1,008	1	8
Other Expenses, net	257	143	36	509	103	144
Total Expenses	1,205	1,544	93	3,571	289	423
Profit / (Loss) Before Exceptional Items and Tax	(605)	(324)	53	(1,385)	52	19
Exceptional Items	-	-	-	-	-	-
Profit / (Loss) before Tax	(605)	(324)	53	(1,385)	52	19
Less: Tax Expense						
Current Tax	-	-	-	-	-	-
Deferred Tax	-	-	-	-	-	-
Profit / (Loss) for the period	(605)	(324)	53	(1,385)	52	19
Other Comprehensive Income / (Expense) (OCI), net of tax expense						
A. Items that will not be reclassified to profit or loss						
Remeasurement of Post Employment Benefit Plans	3	6	1	2	(2)	(12)
B. Items that will be reclassified to profit or loss						
Other Comprehensive Income / (Expense) (OCI), net of tax expense	3	6	1	2	(2)	(12)
Total Comprehensive Income / (Expense) for the period	(602)	(318)	54	(1,383)	50	7
Paid-up Equity Share Capital (Face Value Rs.10/- each)	2,596	2,596	2,596	2,596	2,596	2,596
Reserves (Excluding Revaluation Reserves)						(2,091)
Earnings Per Share (EPS)						
a) Basic and diluted EPS before extraordinary items for the period (Rs.)	(2.3)	(1.2)	0.2	(5.3)	0.2	0.1
b) Basic and diluted EPS after extraordinary items for the period (Rs.)	(2.3)	(1.2)	0.2	(5.3)	0.2	0.1


Piramal Phytocare Limited

CIN : L73100MH2001PLC132523

Registered Office : Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, India
Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400070, India

T +91 22 3802 3000

piramalphytocare.com


Notes:

1. The results for the quarter and nine months ended December 31, 2017 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on January 31, 2018.
2. The Company is engaged in the business of Pharmaceuticals which is the only reportable business segment as per INDAS 108 "Operating Segments".
3. In the current period, the Company has entered into the following transactions (after obtaining necessary approvals) on an arms-length basis, with Piramal Enterprises Limited ('PEL'):
 - (a) Trademark & Knowhow License Agreement for granting an exclusive license to the Company for using specific Trade Marks of PEL against payment of royalty.
 - (b) Distribution Agreement for appointment of PEL as a Distributor for selling Company's products bearing specific trademarks under which the Company would be selling the products to PEL for onward distribution for a distribution margin.
4. The Company has incurred losses in the current period leading to an erosion in its network. However, the management has adequate funding plans which will help the Company continue business operations on a going concern basis for the foreseeable future. Hence, the financial results has been prepared assuming that the Company will continue as a going concern with no adjustments to these financial results.

Mumbai
January 31, 2018



For **PIRAMAL PHYTOCARE LIMITED**


Rajesh Laddha
Director